Filing Analysis
Cardiff Oncology, Inc. filed an 8-K to furnish a press release containing the company's business update and financial results for the second quarter ended June 30, 2026.
📋 Key Facts
- Report date: August 11, 2026
- Reporting period: Second Quarter ended June 30, 2026
- Content: Business update and financial results furnished via Exhibit 99.1
Cardiff Oncology, Inc. announced a combined securities offering of common stock and warrants totaling approximately $10.05 million in gross proceeds. The offering includes significant participation from company insiders at a premium to the institutional price.
🚩 Red Flags
- Related-party transaction: Insiders are participating in the offering at a higher price than institutional investors, which is unusual and may indicate non-standard terms.
- Dilution risk: The issuance of over 8.5 million shares plus warrants (which can convert to another 8.5 million shares) represents significant potential dilution for existing shareholders.
- Capital dependency: Use of proceeds is for 'working capital,' suggesting a need for immediate cash to sustain operations.
📋 Key Facts
- Offered 8,571,429 shares of Common Stock and accompanying warrants to institutional investors at $1.05 per share/warrant unit.
- Offered 721,649 'Insider Shares' and warrants to officers and directors at a higher price of $1.455 per share/warrant unit.
- Gross proceeds from the offering are approximately $10.05 million.
- Warrants have an exercise price of $1.31 for institutional shares and $1.33 for insider shares.
- H.C. Wainwright & Co., LLC acting as exclusive placement agent with a 7.0% cash fee.
- The company must file a proxy statement to obtain stockholder approval for increasing authorized shares to accommodate warrant exercises.
Cardiff Oncology reported the results of its Annual Meeting of Stockholders held on June 11, 2026. The company successfully elected its board of directors, ratified its accounting firm, and approved an increase in shares for its Equity Incentive Plan.
🚩 Red Flags
- Proposal 3 (Equity Incentive Plan increase) showed significant opposition, with 8,063,520 shares voting against the measure, indicating some shareholder dissatisfaction with potential dilution.
📋 Key Facts
- Annual Meeting held on June 11, 2026, with 41,614,848 shares represented (quorum).
- All six director nominees were elected to serve until the 2027 Annual Meeting.
- BDO USA, P.C. was ratified as the independent registered public accounting firm for fiscal year 2026.
- Stockholders approved increasing the 2021 Equity Incentive Plan to 15,150,000 shares.
- Executive compensation received an advisory approval vote.
Cardiff Oncology, Inc. filed a current report to disclose an investor presentation regarding Phase 2 CRDF-004 data and registrational study plans for its drug candidate, onvansertib.
📋 Key Facts
- The filing date is June 3, 2026.
- The company presented Phase 2 CRDF-004 data.
- The presentation outlines registrational study plans for onvansertib.
- The materials were furnished as Exhibit 99.1 and are not deemed 'filed' under Section 18 of the Exchange Act.
Cardiff Oncology is engaged in a legal dispute with Nerviano Medical Sciences S.r.l. (NMS) over patent inventorship and development efforts. On May 27, 2026, NMS formally notified the company of its intent to terminate their March 13, 2017 License Agreement, alleging material breaches.
🚩 Red Flags
- Termination of a core License Agreement by a partner
- Active litigation in U.S. District Court
- Allegations of failure to use 'Commercially Reasonable Efforts' in drug development
- Dispute over patent inventorship which could impact intellectual property ownership
📋 Key Facts
- NMS issued a written notice of termination of the License Agreement on May 27, 2026, citing Section 11.3.
- NMS alleges breach of Section 10.2(c) regarding the failure to include Dr. Barbara Valsasina as a joint inventor on U.S. Pat. Nos. 12,144,813 and 12,263,173.
- NMS further alleges failure to use 'Commercially Reasonable Efforts' for development and regulatory approvals of onvansertib (Sections 7.3, 7.5, and 7.9).
- Cardiff Oncology filed a lawsuit against NMS on May 19, 2026, in the Southern District of California seeking injunctive relief and a declaratory judgment.
- The company maintains that the termination notice is 'legally ineffective, factually unsupported and procedurally improper'.
Cardiff Oncology, Inc. filed a lawsuit on May 19, 2026 against Nerviano Medical Sciences S.r.L (NMS) in the U.S. District Court for the Southern District of California, disputing NMS's allegation that Cardiff materially breached their license agreement for onvansertib, the company's lead drug candidate. Cardiff seeks injunctive relief to compel NMS to continue performing under the agreement and a declaratory judgment that no breach occurred. The dispute centers on inventorship rights related to two Cardiff patents (U.S. Patent Nos. 12,144,813 and 12,263,173), with NMS alleging Cardiff failed to name an NMS employee as a joint inventor.
🚩 Red Flags
- License agreement for onvansertib — Cardiff's lead drug candidate — is at risk of termination if NMS prevails in litigation
- NMS alleged material breach as far back as February 24, 2026; escalation to litigation suggests settlement discussions have failed
- Loss of the onvansertib license could be existential for a micro-cap oncology company with a single lead asset
- Cardiff's need for injunctive relief implies NMS may already be threatening to suspend or terminate performance under the agreement
- Inventorship dispute could cloud the validity and enforceability of Cardiff's key patents (Nos. 12,144,813 and 12,263,173)
- USPTO inventorship integrity concern: Cardiff explicitly states naming NMS employee would be 'false or inaccurate' — potential IP litigation complexity
📋 Key Facts
- Lawsuit filed May 19, 2026 in U.S. District Court for the Southern District of California against Nerviano Medical Sciences S.r.L (NMS)
- Dispute concerns the license agreement for onvansertib, Cardiff's key oncology asset
- NMS alleged material breach in a written notice dated February 24, 2026, roughly 3 months before litigation was initiated
- NMS claims Cardiff failed to name an NMS employee as joint inventor on U.S. Patent Nos. 12,144,813 and 12,263,173
- NMS also alleges Cardiff refused to file a joint invention continuation patent application
- Cardiff maintains it made no breach, asserting inventions were made exclusively by Cardiff and NMS employee listing would constitute false/inaccurate representations to the USPTO
- Cardiff seeks injunctive relief to keep NMS performing under the license agreement and a declaratory judgment of non-breach
- Filing signed by CEO Mani Mohindru; filed under Item 8.01 (Other Events)
Cardiff Oncology, Inc. reported its financial results for the first quarter ended March 31, 2026, and provided a business update. The details were released via a press release on May 14, 2026.
🚩 Red Flags
- The company is currently operating under an Interim CEO, which may indicate a period of management transition.
📋 Key Facts
- Financial results for the quarter ended March 31, 2026, were announced on May 14, 2026.
- The company furnished a press release as Exhibit 99.1.
- The filing was signed by Mani Mohindru in the capacity of Interim Chief Executive Officer.
Cardiff Oncology announced a comprehensive leadership restructuring, appointing a permanent CEO and hiring a new CFO and COO. Mani Mohindru, Ph.D., transitioned from Interim CEO to permanent President and CEO, while Josh Muntner and Ajay Aggarwal were appointed as CFO and COO, respectively.
🚩 Red Flags
- Simultaneous turnover/appointment of the entire C-suite (CEO, CFO, and COO) suggests a period of significant internal transition or prior instability.
📋 Key Facts
- Mani Mohindru, Ph.D. appointed permanent President and CEO with a base salary of $655,000 and a $100,000 bonus.
- Josh Muntner appointed CFO effective April 6, 2026, with a base salary of $475,000 and 486,650 stock options at an exercise price of $1.58.
- Ajay Aggarwal, MD, MBA appointed COO effective April 27, 2026, with a base salary of $490,000 and 400,000 expected stock options.
- Dr. Mohindru received two stock option grants in early 2026 totaling 800,000 shares with exercise prices of $1.56 and $1.62.
- All three executives are eligible for annual discretionary bonuses ranging from 40% to 55% of their base salaries.
Cardiff Oncology finalized separation agreements for its former CEO, Dr. Mark Erlander, and CFO, James Levine, following their departures in January 2026. The agreements involve significant severance payments and the resignation of Dr. Erlander from the Board of Directors as part of a strategic review.
🚩 Red Flags
- Simultaneous departure of both the Chief Executive Officer and Chief Financial Officer.
- Departures occurred in the context of a 'strategic review,' which often signals underlying operational or financial distress.
- Substantial cash severance obligations exceeding $1.1 million in base salaries alone for a micro-cap entity.
📋 Key Facts
- Former CEO Dr. Mark Erlander will receive a base salary of $635,000 over 12 months and a 2025 bonus of $122,238.
- Former CFO James Levine will receive a base salary of $490,000 over 12 months and a 2025 bonus of $61,740.
- Dr. Erlander resigned from the Board of Directors effective March 27, 2026.
- Both executives are entitled to 50% of their 2026 target bonuses on a pro-rated basis and 12 months of healthcare benefits.
- Dr. Erlander entered into a consulting agreement with the company, with stock options continuing to vest until June 2026.
- The departures were previously disclosed on January 26, 2026, as part of a 'strategic review'.
Cardiff Oncology, Inc. furnished a corporate slide presentation under Regulation FD for use in upcoming meetings with third parties. The filing includes the presentation as Exhibit 99.1 and was signed by the Interim CEO.
🚩 Red Flags
- The company is currently operating under an Interim CEO (Mani Mohindru), which may indicate leadership transition or instability.
📋 Key Facts
- The filing was made on February 25, 2026, under Item 7.01 Regulation FD Disclosure.
- The company intends to use the corporate slide presentation in meetings with third parties.
- Mani Mohindru is identified as the Interim Chief Executive Officer.
- The information in the report is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Cardiff Oncology announced its full-year 2025 financial results and provided a business update on February 24, 2026. The report was signed by Mani Mohindru in the capacity of Interim Chief Executive Officer.
🚩 Red Flags
- The company is currently led by an Interim CEO, indicating a period of leadership transition.
📋 Key Facts
- Financial results for the full year ended December 31, 2025 were released on February 24, 2026.
- The filing includes a business update alongside the financial data.
- Mani Mohindru is currently serving as the Interim Chief Executive Officer.
- The press release is furnished as Exhibit 99.1 under Item 9.01.
Cardiff Oncology announced a major leadership overhaul on January 27, 2026, involving the departure of both the CEO and CFO following a strategic leadership review. Dr. Mani Mohindru has been appointed as interim CEO to stabilize operations.
🚩 Red Flags
- Simultaneous departure of both CEO and CFO is a significant governance red flag.
- Departures triggered by a 'strategic leadership review' often suggest internal friction or shifts in corporate direction.
- Leadership instability during clinical trial updates can create market volatility.
📋 Key Facts
- CEO Dr. Mark Erlander, Ph.D. stepped down on January 27, 2026.
- CFO James Levine stepped down on January 27, 2026.
- Dr. Mani Mohindru (Board Member) appointed as interim CEO.
- Brigitte Lindsay promoted from SVP Finance to Chief Accounting Officer.
- The departures are part of a 'strategic leadership review'.
- Company reported positive Phase 2 clinical trial updates for CRDF-004 (onvansertib) in mCRC patients.
Cardiff Oncology, Inc. filed an 8-K to furnish its third quarter financial results and company highlights for the period ended September 30, 2025.
📋 Key Facts
- The filing is a routine disclosure of quarterly financial results (Item 2.02).
- Reporting period: Third Quarter ended September 30, 2025.
- Filing date: November 6, 2025.
- The company furnished an earnings press release as Exhibit 99.1.
Cardiff Oncology announced positive clinical data from its Phase 2 trial (CRDF-004) for RAS-mutated metastatic colorectal cancer and released its Q2 2025 financial results. The filing includes a corporate presentation detailing the clinical progress.
📋 Key Facts
- Announced positive data from ongoing randomized phase 2 first-line RAS-mutated metastatic colorectal cancer (mCRC) clinical trial CRDF-004.
- Released Q2 2025 financial results and company highlights via press release dated July 29, 2025.
- Provided a corporate presentation regarding the positive clinical data findings.
Cardiff Oncology, Inc. held its Annual Meeting of Stockholders on June 26, 2025. The results included the election of seven directors and the ratification of BDO USA, P.C. as independent auditors.
🚩 Red Flags
- Significant 'Broker Non Vote' numbers across all proposals (approx. 16.6M shares), suggesting a high level of non-participation or uninstructed proxies in the voting process.
📋 Key Facts
- Annual Meeting held on June 26, 2025, with a quorum of 38,649,891 shares represented.
- All seven director nominees were elected to serve until the 2026 Annual Meeting or their respective successors.
- Stockholders ratified BDO USA, P.C. as the independent registered public accounting firm for fiscal year ending December 31, 2025.
- An amendment to the 2021 Equity Incentive Plan was approved, increasing the number of issuable shares by 12,150,000.
- Advisory vote on executive officer compensation (Say-on-Pay) was approved.
Cardiff Oncology, Inc. announced a leadership transition in its medical department, involving the departure of Chief Medical Officer Dr. Fairooz Kabbinavar and the appointment of Dr. Roger Sidhu as his successor.
🚩 Red Flags
- Succession timing: The departure and appointment occurred within a very tight window (June 13 to June 17), which can sometimes indicate internal friction, though the transition to an advisory role suggests a planned exit.
📋 Key Facts
- Dr. Fairooz Kabbinavar stepped down as Chief Medical Officer on June 13, 2025; he will transition to an advisory role.
- Dr. Roger Sidhu was appointed as the new Chief Medical Officer effective June 16, 2025.
- Dr. Sidhu's compensation includes a $515,000 annual base salary and a target performance bonus of 45% of base salary.
- Dr. Sidhu received an inducement grant of 600,000 non-qualified stock options with an exercise price of $3.86 per share.
- The option vesting schedule includes 25% on June 16, 2026, followed by monthly installments over 36 months.
Cardiff Oncology, Inc. filed an 8-K to furnish its first quarter financial results and company highlights for the period ended March 31, 2025.
📋 Key Facts
- The filing is a routine disclosure of quarterly financial results (Item 2.02).
- Reporting period: First Quarter ended March 31, 2025.
- Filing date: May 8, 2025.
- Includes Exhibit 99.1 containing the press release with company highlights.
Cardiff Oncology, Inc. filed an 8-K to furnish its fourth quarter financial results and company highlights for the period ended December 31, 2024.
📋 Key Facts
- Report date: February 27, 2025
- Reporting period: Fourth quarter ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results and company highlights.
Cardiff Oncology, Inc. filed an 8-K to announce that its Board of Directors approved Amended and Restated By-laws on January 3, 2025.
📋 Key Facts
- Board of Directors approved the Amended and Restated By-laws of the Company on January 3, 2025.
- The filing includes the updated By-laws as Exhibit 3.1.
Cardiff Oncology, Inc. entered into an underwriting agreement to sell 15,384,619 shares of common stock at $2.60 per share, aiming to raise approximately $40 million in gross proceeds. The funds are earmarked for clinical costs related to onvansertib and general working capital.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of over 15 million new shares.
- The offering is being conducted via a shelf registration (Form S-3), indicating an ongoing need for capital in a pre-revenue/clinical stage environment.
📋 Key Facts
- Offering size: 15,384,619 shares of common stock.
- Expected gross proceeds: Approximately $40 million.
- Offering price: $2.60 per share.
- Underwriter/Representative: TD Securities (USA) LLC.
- Use of proceeds: Clinical costs for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC), working capital, and general corporate purposes.
- Lock-up period: Directors and executive officers are subject to a 90-day non-transfer restriction.
- Expected closing date: On or about December 11, 2024.
Cardiff Oncology announced positive initial data from its CRDF-004 Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care for first-line RAS-mutated metastatic colorectal cancer (mCRC). The company also plans to present related materials via a conference call.
📋 Key Facts
- Announcement of positive initial data from the CRDF-004 Phase 2 clinical trial.
- Trial evaluates onvansertib + standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC).
- The filing includes a corporate presentation (Exhibit 99.1) and a press release (Exhibit 99.2).
- Date of event: December 10, 2024.
Cardiff Oncology, Inc. filed an 8-K to furnish its quarterly press release containing company highlights and financial results for the second quarter ended September 30, 2024.
📋 Key Facts
- The filing is a standard disclosure of quarterly results via Exhibit 99.1.
- Reporting period: Second quarter ended September 30, 2024.
- Filing date: November 7, 2024.
Cardiff Oncology, Inc. filed an 8-K to furnish its second quarter 2024 financial results and company highlights as of the period ended June 30, 2024.
📋 Key Facts
- The filing is a standard quarterly earnings release (Item 2.02).
- Reporting period: Second Quarter ended June 30, 2024.
- Filing date: August 8, 2024.
Cardiff Oncology, Inc. held its Annual Meeting of Stockholders on June 20, 2024. The filing reports the results of stockholder votes regarding director elections, auditor ratification, equity plan amendments, and executive compensation.
📋 Key Facts
- Annual Meeting held on June 20, 2024, with a quorum of 27,736,982 shares represented.
- All seven (7) director nominees were elected to serve until the 2025 Annual Meeting or successors.
- Stockholders ratified BDO USA, P.C. as the independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- An amendment to the 2021 Equity Incentive Plan was approved to increase shares issuable by 8,150,000 shares.
- The advisory vote on executive officer compensation (Say-on-Pay) was approved.
Cardiff Oncology amended its bylaws to clarify voting standards and rescinded a previous stock option grant to re-issue the same number of shares under a new authorization. The filing also notes an upcoming annual meeting on June 20, 2024, where shareholders will vote on increasing the share pool for equity incentives.
🚩 Red Flags
- Potential dilution: The re-granting of options requires a shareholder vote to increase the available share pool, which could lead to further dilution if approved.
📋 Key Facts
- Amended Bylaws: Directors are to be elected by plurality; other matters require a majority of voting power present at a meeting.
- Rescinded 1,697,712 shares of common stock issuable upon exercise of options granted on March 7, 2024 (exercise price $3.51).
- Re-granted 1,697,712 shares of common stock issuable upon exercise of options at an exercise price of $3.51.
- The new grant is subject to stockholder approval for an increase in the 2021 Equity Incentive Plan pool.
- Annual meeting scheduled for June 20, 2024.
Cardiff Oncology, Inc. filed an 8-K to furnish its quarterly financial results and company highlights for the first quarter ended March 31, 2024.
📋 Key Facts
- The filing pertains to the first quarter (Q1) ended March 31, 2024.
- Company issued a press release containing financial results as Exhibit 99.1.
- Report date is May 2, 2024.
Cardiff Oncology, Inc. issued a press release via Regulation FD disclosure regarding the presentation of five abstracts at the American Association for Cancer Research (AACR) conference held in April 2024.
📋 Key Facts
- Company presented five abstracts at the AACR conference (April 5-10, 2024).
- The filing is a Regulation FD disclosure intended to provide public access to scientific data/presentations.
- Information provided in Exhibit 99.1 is furnished but not 'filed' for purposes of Section 18 liability.
Cardiff Oncology announced its fourth quarter and full year 2023 financial results alongside significant clinical updates. The company reported the first patient dosing in its Phase 2 CRDF-004 trial for RAS-mutated metastatic colorectal cancer.
📋 Key Facts
- Released Q4 and Full Year 2023 financial results on February 29, 2024.
- Provided clinical update regarding the ONSEMBLE trial (second-line RAS-mutated mCRC).
- Announced first patient dosing in the randomized first-line Phase 2 CRDF-004 trial for RAS-mutated mCRC.
Cardiff Oncology, Inc. filed an 8-K to provide a corporate slide presentation in connection with upcoming meetings with third parties under Regulation FD.
📋 Key Facts
- The company intends to conduct meetings with third parties using its corporate slide presentation.
- A copy of the presentation materials is attached as Exhibit 99.1.
- Information provided under Item 7.01 is furnished but not 'filed' for purposes of Section 18 liability.